|MDACC Study No:||RTOG1203 (clinicaltrials.gov NCT No: NCT01672892)|
|Title:||A Randomized Phase III Study of Standard vs. IMRT Pelvic Radiation for Post-Operative Treatment of Endometrial and Cervical Cancer (TIME-C) |
|Principal Investigator:||Ann Klopp|
|Treatment Agent:||Cisplatin; Radiation|
|Study Description:||The goal of this clinical research study is to find out if using a radiation |
delivery method called intensity-modulated radiation therapy (IMRT) leads to
fewer and/or less severe gastrointestinal side effects (such as diarrhea) than
standard radiation delivery.
IMRT is designed to give radiation to the areas that your doctor thinks may
have cancer cells. It is also designed to lower the amount of radiation that
nearby normal tissues (such as the small and large intestine) receive.